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The Complement System is an important component of innate immunity, 
whose activation has been associated with acute inflammation.  Activation of 
complement leads to the generation of a Membrane Attack Complex (MAC) 
composed of C5b-C9 proteins. The function of the MAC has been primarily 
associated with target cell death through the polymerization and insertion of C9 on 
the surface of complement activating particles. Here, I provide evidence that MAC 
assembled on the surface of complement activating particles, can be transferred to 
host macrophages during the process of phagocytosis. This “bystander activation” 
onto macrophages causes potassium efflux and ROS production, which induces the 
assembly of the NLRP3 inflammasome, which in turn results in the activation of 
caspase-1 and the processing and secretion of IL-1β and IL-18 to regulate both 
innate and adaptive immunity. Inflammasome activation is not induced when 
macrophages phagocytize unopsonized particles or particles opsonized with serum 
deficient in one of the terminal complement components. The secretion of IL-1β 
and IL-18 by macrophages is dependent on NLRP3, ASC, and caspase-1, as 
macrophages deficient in any one of these components fail to secrete these 
 
 
cytokines following complement-mediated phagocytosis. The phagocytosis of 
complement-opsonized particles increases leukocyte recruitment and promoted 
Th17 biasing.  
Leishmania major, an intracellular pathogen, follows a similar pattern, 
when infecting macrophages:  Phagocytosis of the pathogen was accompanied by 
the activation of complement pathway resulting in “bystander activation” and 
NLRP3 inflammasome assembly. When macrophages are primed with IFN and 
IL-1β together prior infection, the killing of parasites is enhanced demonstrating 
that IL-1β can work in concert with IFNγ to activate macrophages and thus reduce 
the intracellular burden of the pathogen. This study demonstrates that the 
phagocytosis of complement-opsonized particles can induce inflammasome 
activation by a novel mechanism involving MAC-mediated “bystander activation” 
of host macrophages.  This work provides another mechanism whereby 
complement activation can lead to acute inflammation and identifies a previously 
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Chapter 1: Introduction 
1.1 Innate Immunity 
Innate immunity represents the first line of defense against pathogens. It 
consists of a broad spectrum of responses to different pathogens or environmental 
cues. Innate immunity is limited by the fact that these responses are not specific to 
particular antigens and do not confer long lasting memory. However, innate 
immunity acts quickly and provides vital resistance to the host until the adaptive 
immune response is properly activated. 
Apart from anatomical barriers like skin and the mucous membranes which 
provide nonspecific physical barricades to the invading pathogen, there are two 
main components of innate immunity: (i) humoral factors (e.g. the complement 
system, and the coagulation pathway, etc.) and (ii) cellular components (e.g. 
macrophages and neutrophils). Activation of humoral factors in response to a 
pathogens is instantaneous. The coagulation cascade can induce blood clotting to 
limit the entry of pathogens. Complement components bind to pathogen, thus 
tagging them to be taken up by phagocytes. Complement can also form membrane 
attack complexes (MAC) on the surface to lyse pathogens. The activated 
components from the coagulation and complement cascades induce the infiltration 
of leukocytes including neutrophils, macrophages and dendritic cells (DC), which 
leads to inflammation. The cellular components of the innate immune system are 
adept at actively taking up pathogens through the process of phagocytosis, for 
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destruction in the phagolysosome and subsequent processing for antigen 
presentation, hence they are termed professional phagocytes.  
One critical role of the innate immune system, apart from first response to 
infectious pathogens, is to identify and discriminate healthy and damaged tissues. 
Sensing tissue stress helps the immune system to simultaneously induce 
inflammation and tissue repair thereby maintaining homeostasis. It is now apparent 
that there are a variety of Pattern Recognition Receptors (PRRs) on innate immune 
cells that serve to identify Pathogen Associated Molecular Patterns (PAMPs) and/or 
Danger Associated Molecular Patterns (DAMPs)1. While PAMPs are derived from 
microorganisms, DAMPs are cell-derived in response to trauma and tissue damage 
that occurs either in the absence or presence of pathogenic infection. DAMPs 
constitute a large family of endogenous molecules that include alarmins, heat shock 
proteins, extracellular ATP, low molecular weight hyaluronic acid, HMGB1, uric 
acid etc. Exposure to these molecules triggers the innate immune system and directs 
its activity towards resolution of danger and tissue distress. The innate immune 
cells then initiate the adaptive immune responses; which can include cell-mediated 
immunity or humoral immunity mediated by T or B cells, respectively. This 
adaptive response enables the host to “remember” the pathogen, which ensures that 
any secondary infections will lead to a stronger immune response and the rapid 
clearance of the pathogen. 
Janeway suggested that PRRs were important for the initiation of adaptive 
immunity2. The seminal work that identified the first PRR was provided by Le 
Maître and Hoffman when they demonstrated that mutant flies lacking a functional 
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Toll protein were susceptible to fungal infections3. This initiated an avalanche of 
studies to identify PRRs and understand how innate immunity could initiate and 
shape adaptive immune responses 4. Since then, many surface and cytosolic PRRs 
have been identified in higher vertebrates and throughout evolution, and we are 
beginning to understand how signaling through these receptors allows for the 
initiation of adaptive immune responses. We have also come to realize that the 
activation of these PRRs can lead to inflammatory immunopathology. Therefore 
studies to understand how PRR signaling can be modified or interrupted are 
providing new hope for the development of therapeutics to treat inflammatory 
diseases5. 
There are two major consequences of ligating PRRs on immune cells. The 
first is to signal danger to the cells and to initiate a cascade of responses that can 
help to direct host defense responses. Most of these responses are in the form of 
cytokines or antimicrobial compounds that are produced by leukocytes in response 
to PRR stimulation. The second important consequence is to induce the competency 
of select cells to present antigen to T cells. The presentation of antigen by antigen 
presenting cells (APCs) is necessary to initiate adaptive immune responses. PRR 
stimulation induces DC maturation to stabilize MHC molecules on their surface 
and facilitates antigen presentation by inducing the expression of co-stimulatory 
molecules on APCs to induce T cell proliferation and differentiation. Thus, the 
ligation of PRRs can benefit the host in two ways. First it can initiate innate immune 
responses to kill pathogens directly, and if those responses are not sufficient to clear 
4 
 
the pathogen it can initiate antigen-specific adaptive immune responses to provide 
the next layer of protection6. 
1.1.1 Macrophages 
An important component of the innate immune system is the macrophage. 
Macrophages are important phagocytes in the host as they serve two general 
functions.  The first is the maintenance of homeostasis, which involves the 
regulation of iron metabolism, the clearing of apoptotic cells, and tissue 
regeneration. The second general function is host defense. As an innate immune 
effector cell, macrophages are involved in the phagocytosis of foreign particles, and 
the elimination of pathogens7. During inflammation, macrophages are primarily 
derived from precursor monocytes that are derived from the hematopoetic stem 
cells in the bone marrow and continuously circulate in the bloodstream. These cells 
constantly replenish tissue macrophages after exiting the bloodstream to reside in 
the tissue and becoming resident cells. Based on the anatomical site, the 
macrophages in different tissues are termed osteoclasts (bone), microglia (CNS), 
Kupffer cells (liver), histiocytes (connective tissue), and alveolar macrophage 
(lung). These tissue specific macrophages have their own specialized functions in 
maintaining homeostasis and providing the first line to defense against pathogens. 
Macrophages express PRRs that help in identifying DAMPs and PAMPs. 
They are generally of two types: cell surface receptors such as toll-like receptors 
(TLRs), mannose receptor and other lectin receptors; and cytosolic receptors, 
including NOD-like Receptors (NLRs) and RNA helicases. The presence of 
multiple PRRs helps macrophages to identify a broad range of pathogens. The 
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ligation of these receptors enables macrophage activation. These receptors activate 
transcription factors such as NF-κB and IRFs that are involved in the synthesis of 
many proinflammatory cytokines such as IL-1β, TNF, IL-12, IL-6, and IFNγ etc. 
that play an important role in anti-microbial defense8.  
Macrophage activation shows remarkable plasticity as their phenotype is 
regulated by the sum of all environmental signals, with dynamic changes occurring 
over time. Macrophages can be broadly classified according to their fundamental 
roles in maintaining different aspects of homeostasis. Classically activated 
macrophages (CA-M) are activated by a combination of IFNγ and TNF. They 
have been shown to be important to eliminate intracellular pathogens like 
Leishmania spp. and thus are an important component of the delayed type 
hypersensitivity reaction. Although they are considered important in host defense 
against pathogens, their actions need to be regulated as their indiscriminate 
microbicidal properties can also lead tissue damage to the host that can cause 
autoimmune diseases9. Regulatory macrophages, (R-Mϕ), a subset of macrophages 
that were first described in this lab10, in contrast to classically activated 
macrophages, are characterized by high production of the anti-inflammatory 
cytokine IL-10 and decreased production of IL-1211. R-Mϕ are generated by two 
signals. The first signal (immune complexes, prostaglandin E2, adenosine, 
apoptotic cells, etc.) does not significantly induce cytokines on its own, but in 
combination with a second stimulus like TLR ligands, can subvert macrophage 
activation to produce anti-inflammatory cytokines. R-Mϕ are thought to be present 
during the initial innate immune response to control inflammation and also during 
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late stages of the adaptive immune response to limit cytotoxicity. Since they are 
immuno-suppressive in nature, R-Mϕ can be exploited by different pathogens. 
Viruses can use antibodies to enhance their ability to infect while inducing the 
production of anti-inflammatory cytokines12. Leishmania spp. and Bacillus 
anthracis have been shown to induce the production of these Mϕ subsets to 
establish an infection13. Wound healing macrophages or alternatively activated 
macrophages (AA-Mϕ) form a third type of macrophages that are derived by IL-4 
and/or IL-13 activation14. IL-4 is generated by basophils early during an immune 
response and later by Th2 cells. AA-Mϕ have been shown to be involved in the 
generation of extracellular matrix by stimulating arginase activity15 important in 
clearing helminthes and nematodes. AA-Mϕ have been reported to be more 
permissive to intracellular pathogens like M. tuberculosis, L. major, and F. 
tularensis, possibly because they fail to produce nitric oxide16,17. All three 
populations of activated macrophages govern critical functions in the host, and 
consequently all of their activation responses must be tightly controlled to avoid 
potential complications.  
1.1.2 Inflammasome 
The inflammasome is a term used to describe a molecular platform that activates 
inflammatory caspases leading to the maturation and secretion of important 
cytokines like IL-1β and IL-1818. Inflammasomes are multi-protein oligomers 
composed of leucine-rich repeat containing receptors (NLRs), adaptor molecules 
like apoptosis-associated speck-like protein containing a CARD (ASC), and 
caspase-1. Sometimes human capase-5, and mouse caspase-11 are found to be 
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recruited to NLRP1 inflammasomes19. They are termed inflammasomes in analogy 
to another caspase activating platform found on cells that controls apoptosis and is 
known as the apoptosome20. There are three prototypical inflammasomes: 
NLRP1inflammasomes, NLRP3 inflammasomes and NLRC4 inflammasomes21. 
Caspase-1 is a cysteine protease that is normally present as an inactive precursor in 
the cytosol, known as a procaspase. Once the inflammasome is activated, multiple 
procaspase-1 molecules are brought close to each other and in an autocatalytic 
reaction are cleaved into mature enzymes. Activation of caspase-1 occurs 
downstream of the signaling of several members of the NLR family of cytosolic 
receptors (Figure 1). 
1.1.3 NLRs 
NLRs are composed of C terminal leucine-rich repeats (LRRs) that bind to 
ligands, a central NACHT domain that results in NLR oligomerisation, and an N 
terminal effector domain (CARD or PYD). The NLRs can be subdivided into many 
subfamilies based on their structure; NLRA (CCTIIA), NLRB (NAIP), NLRC 
(NOD1, NOD2, IPAF etc), NLRP (14 NLRPs have been identified to date) and 
NLRX (NOD9)22. Their tissue distribution is varied. For example, while NLRP1 is 
widely expressed in many tissues, NLRP3 is expressed in immune cells and 
epithelial cells. NLRP4, 5, 7, 8, 10, and 11 are expressed in germ cells. IPAF and 
NAIP are expressed in brain, spleen, liver lung and other macrophage rich tissues. 
Their expression can be up-regulated by ligation of TLRs thus demonstrating the 
capability of NLRs to synergize with TLRs during an immune response23.  
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The basic mechanisms involved in the activation of caspase-1 are quite 
similar for the subfamilies, but they might require additional molecules; for 
example NLRP1 and NLRP3 inflammasomes require ASC to interact with the N 
terminal PYD domain of the NLRs and recruit caspase-1. The NLRP1 
inflammasome can also interact with caspase-5 through its C terminal CARD 
domain. IPAF can directly interact with caspase-1 through its N terminal CARD 
domain. All of NLRs require ATP to bind to the NACHT domain to initiate 
oligomerization thus forming a “donut shaped” platform24 for caspase-1 to be 
activated.  
The importance of caspase-1 in innate immunity is shown by caspase-1 
deficient mice that have a defect in the maturation of IL-1β and IL-18 and are more 
resistant to endotoxic shock25. Caspase-1 knockout mice are more permissive to 
Listeria infections during the initial phase of the infection26. IL-18 is best known as 
a stimulator of NK cell activity, inducing IFNγ from splenocytes along with IL-12 
and up-regulating adhesion molecules The proinflammatory properties of IL-1β 
include up-regulation of adhesion molecules, influencing leukocyte recruitment by 
inducing chemokines, induction of fever, reducing pain threshold, vasodilation and 
hypotension27. 
1.1.4. NLRP1 Inflammasome 
The NLRP1 inflammasome contains molecules of NLRP1, ASC, caspase-1 
and sometimes caspase-5. The NLRP1 inflammasome has been implicated in 
anthrax caused by Bacillus anthracis28 infection. Anthrax lethal toxin is one of the 
major virulence factors that can cause systemic infections, possibly through the 
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activation of NLRP1 inflammasome29. Polymorphisms in NLRP1b have been 
identified and shown to be required for mouse macrophage susceptibility to anthrax 
lethal toxin30. Although the exact mechanism of NLRP1 activation has not been 
shown, binding, uptake, endosome acidification and final translocation of the lethal 
factor have been shown to be important in caspases-1 activation. NLRP1 can 
associate with ASC through its PYD domain in the N terminal and can recruit 
caspase-1 through the card domain leading to the activation of caspase-1. Through 
its C terminal CARD it can either bond to a second molecule of caspase-1 or recruit 
caspase-5. The activation of these caspases is known to be required for IL-1β 
processing and release. Their activation is also known to induce pyroptotic cells 
death in macrophages. 
1.1.5. NLRC4 inflammasome 
NLRC4 (IPAF) has been shown to be required for inflammasome activation 
upon interacting with Salmonella typhimurium31. NLRC4 deficient mice were 
found to be resistant to IL-1β release by S. typhimurium- and host cell death. 
Bacterial flagellin is reported to be the ligand for NLRC4 as it has been shown that 
purified flagellin can induce caspase-1 activation when introduced directly into the 
cytosol. NLRC4 can directly activate caspase-1 through its N terminal CARD 
domain. Although the role of ASC is unclear, it is proposed to stabilize the caspase-
1 interaction with NLRC432. Flagellin-dependent caspases-1 activation requires a 
type three-secretion system in bacteria as it has been shown that Pseudomonas 
aeruginosa also activates NLRC4, and mutations in its type three-secretion system 
abrogate the release of IL-1β. 
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1.1.6. NLRP3 Inflammasome 
NLRP3 is the most well characterized inflammasome and it consists of 3 
proteins; NLRP3, ASC and caspase-1. The NLRP3 inflammasome has been 
implicated in responding to environmental stress and danger. Auto-inflammatory 
diseases like familial cold induced auto-inflammatory syndrome and Muckle Wells 
syndrome have been linked to mutations in the NLRP3 gene. There are many 
NLRP3 activators that include both exogenous and endogenous danger signals33. 
Since all these activators lack obvious similarities in their structure or function, it 
is hypothesized that they can activate a common endogenous molecule that can 
serve as a NLRP3 ligand21. Inspite of these observations, the precise mechanism of 
NLRP3 inflammasome activation is not known. Three models of NLRP3 activation 
have been proposed: (i) pore formation inducing potassium efflux and membrane 
permeabilization which induce direct interaction of an agonist with NLRP3; (ii) 
phagocytosis of crystalline particles can cause lysosomal damage triggering release 
of cathepsins from lysosome enabling the activation; and (iii) NLRP3 agonist 
induced K+ efflux can trigger the activation of the inflammasome. As shown in 
Figure 1, upon activation, NLRP3 oligomerizes to form a platform for ASC 
interaction through the PYD domains. The CARD domain on ASC then interacts 
with procaspase-1. Procaspase-1 clustering leads to the autocatalytic reaction 
leading to caspase-1 activation. Caspase-1 then cleaves its substrates IL-1β and IL-
18. Caspase-1 along with IL-1β and IL-18 are secreted into the extracellular space 
through a non-classical mechanism. Secretory lysosomes, micro-vesicle shedding 
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and the presence of dedicated transporters are implicated in the secretion of 









Figure 1: The Activation of NLRP3 Inflammasome: 
TLR Primed BMMϕ expresses NLRP3 inflammasome and proIL-1β protein. When 
macrophages are exposed to danger signals like extracellular ATP or bacterial toxins or 
phagocytosis of crystalline particles like monosodium urate or silica, the membrane 
potential of macrophages is perturbed. This causes loss of K+ ions from the cell triggering 
the assembly of NLRP3 inflammasome which is composed of NLRP3, ASC and pro-
caspase-1 in a specific area of the cell and form a speck. They serve as platforms for the 
generation of activated caspase-1. Activated caspase-1 then promotes the maturation and 
secretion of mature IL-1β and IL-18. 
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1.2. Complement System 
The complement system is a serine protease enzymatic cascade composed 
of a group of soluble plasma proteins, which can become activated to bind to 
foreign surfaces. The fact that the basic components of the complement system are 
found in many species with conserved biochemical properties signifies the 
importance of the system in the host. There are three distinct pathways of 
complement activation, called the Classical, the Alternative, and the Lectin 
pathways. Antibody bound to an antigen can activate the Classical complement 
pathway. Some foreign surfaces can directly activate the Alternative complement 
pathway and the recognition of microbial polysaccharides on cell surfaces can 
activate the Lectin pathway. The three different pathways converge by activating 
C3 and later C5, leading to the formation of Membrane Attack Complex (MAC), 
which is assembled by the sequential addition of late complement components C5-
C9. For a  time after the discovery of complement, the formation of MAC was 
believed to be the only function of the complement system35. Now it is known that 
complement has many important biological functions in regulating the immune 
response  including activation and recruitment of leukocytes via anaphylatoxins; 
opsonization of pathogens  to promote phagocytosis; and clearance of immune 
complexes and apoptotic cells from circulation36. Patients with complement 
component deficiencies are usually given prophylactic antibiotics as complement 
plays an important role in host defense to various pathogens 
1.2.1 Complement Activation 
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There are three major pathways of complement activation, classical, 
alternative and lectin, which converge at the level of C3. All three pathways 
thereafter share a common sequence through the late components C5, C6, C7, C8 
and C9, leading to the generation of the MAC. As shown in Figure 2 the classical 
pathway is initiated by C1 when it recognizes antibody bound antigen. Being a 
multimeric complex with serine esterase activity C1 cleaves C4. The resulting C4b 
fragment has a binding site for C2, which allows C1 to cleave the zymogen C2. 
Cleaved C2 (a serine protease) proteolytically activates C3 and then C5 though the 
formation of C3 and C5 convertases. The phylogenetically older alternative 
pathway is activated by the constant ticking over of C3 to C3b. Using fragments of 
C3 and factor B it forms  the bimolecular enzyme C3bBb after being activated by 
factor D which circulates as an active serine esterase. However, the pathway is 
normally restricted because the inhibitor factor H prevents the binding of factor B 
with C3b, and factor D is only able to cleave B that is bound to C3b. The ability of 
factor H to discriminate between host and microbial carbohydrate determinants 
provides the specificity for activation of the alternative pathway. The lectin 
pathway is initiated when mannose binding lectin bids to polysaccharies on 









Figure 2: Complement activation: 
The three major pathways of complement activation are shown (lectin pathway is 
initiated by mannose binding lectin). These pathways lead to the formation of C3 
convertases (C4b2b represents the classical/lectin pathway C3 convertase, and 
C3bBb the alternative pathway C3 convertase), which activate the central 
component C3. The C3b fragment can bind to the existing convertases and thus 
form the C5 convertases of the classical/lectin pathway (C4b2b3b) or the 
alternative pathway (C3bBbC3b). C5 convertase is essential for the activation of 
the common terminal pathway, which leads to the generation of the lytic membrane 
attack complex composed of C5b, C6, C7, C8, and C9. The C3b fragment is also a 
major opsonin, mediating phagocytosis via C3-fragment receptors on phagocytes. 
The generated C3a and C5a are potent anaphylatoxins that are involved in the 
activation of various cell types and mediate inflammatory processes.  
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1.2.2 Activation of the Late Components 
The activation of the late components is initiated by a C5 convertase which 
results in the formation of the “active” form of C5 termed C5b. It is a short lived 
molecule still associated with the convertase which then binds to C6. The resulting 
C5b6 complex is stable and can initiate the formation of the MAC on its own. C5b6 
can reversibly associate itself with membrane and other hydrophobic surfaces but 
the binding of C7 yields a stable trimolecular complex that exposes for a few 
milliseconds hydrophobic domains on the complex that is bound to the membrane 
that can associate with C8. The addition of C7 to C5b6 forms C5b6737. If C5b67 
collides with a lipid membrane during this short interval, the C5b67 inserts in the 
membrane; if not, the C5b67 rapidly decays in the fluid phase. A domain on 
membrane bound C5b67 provides a binding site for C8. Although lysis of cells can 
be detected  at this stage, it is substantially enhanced by the addition of C9 which 
forms the characteristic pore that results in lysis38. 
Complement activation can be separated into the activation step that ends 
with the formation of the C5 convertase and the effector step involving the late 
components. Only the latter effector step is essential for the lysis of target cells. 
More than 40 years ago, it was demonstrated that it was possible to lyse un-
sensitized cells (cells lacking activating convertases) as experimentally shown by  
“reactive lysis” experiments pioneered by Lachmann 39. The modulation of what is 
now referred to as “bystander activation” was shown to depend on many fluid phase 
factors like the presence of poly-cations and pH.  We propose that during  
inflammation this phenomenon of innocent bystander activation of the MAC on 
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cells other than the target could have important consequences in modulating the 
immune/inflammatory processes40. 
1.2.3 Lytic and sublytic MAC 
Complement was first recognized because of its capacity, in conjunction 
with antibody to lyse cells, in particular, bacteria. Complement mediated lysis is an 
important part of the response to infectious organisms, utilized as a defense not 
only in the early stages of infection, but also once adaptive immunity has 
developed. The key molecule in the MAC is C9 which inserts through the cell 
membrane and is then able to polymerize to form the “pore” of the MAC. When C9 
is present in low copy numbers these pores form rigid, hollow protein-lined 
channels41. Erythrocytes were among the first cells to be investigated with regard 
to the lytic mechanism of complement action, and they are still used extensively 
today. It has been shown that a single functional MAC in the membrane of a 
metabolically inert, aged erythrocyte is sufficient to lyse the cell by colloid osmosis. 
Not surprisingly, the efficiency with which lysis occurs depends on the number of 
MACs in the cell membrane, and on the composition of the extracellular fluid. This 
simple picture of osmotic cell lysis does not extend to analyses of MAC-mediated 
killing of nucleated cells42. More subtle cell-damaging effects of the MAC would 
therefore not be detected in this model, resulting in the popular view of the MAC 
as a moiety which rapidly and efficiently kills cells. Unlike in erythrocytes, several 
channels are required to lyse a metabolically active nucleated cell or bacteria. The 
multichannel requirement for nucleated cell lysis has been attributed to a defense 
response of the cell though ion pumps to stabilize membrane polarization and to 
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promote elimination of terminal complement complex (TCC) from the PM by 
endocytosis or by endocytosis and vesiculation. Complement- mediated lysis of 
nucleated cells displays “multi-hit” kinetics, implying a requirement for many 
MACs on the cell surface, and factors other than colloid osmotic dysregulation, 
notably the presence of calcium in the extracellular fluid, influence the efficiency 
of killing. Host cells are also endowed with abundant complement regulatory 
proteins like CD59, CD55 and CD46. Nucleated cells are thus more difficult to kill 
with antibody and complement than are metabolically inert targets like aged 
erythrocytes or liposomes43,44. 
The MAC however has been implicated in a variety of other non-lytic 
effects that differ according to the nature of the target cell and the system 
interrogated. Especially when formed on phagocytes (neutrophils and 
macrophages), metabolically active cell types that are intrinsically resistant to 
complement-mediated lysis, the MAC induces profound activation with the 
production and release of inflammatory mediators such as prostaglandins, 
thromboxanes, leukotrienes and reactive oxygen species45. These processes aid in 
the activation of the immune system by stimulating the inflammatory response and 
arming the host immune system to deal with invading organisms or danger signals. 
1.2.4 The Role of MAC in Inflammatory diseases  
The MAC can be implicated in a disease process based on the demonstration 
of increased consumption of terminal complement components or production of 
terminal complement complexes (SC5b-9 or MAC) in biological fluids, 
localization of the MAC in diseased tissue or abrogation of the disease by inhibition 
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of MAC-producing capacity. The availability of antibodies specific to neo-antigens 
of terminal complement complexes  has made their measurement in biological 
fluids and localization in diseased tissue a relatively simple process and has 
stimulated an interest in TCCs, reflected in a large number of publications, and an 
increasingly long list of diseases in which TCCs are implicated40. 
The first disease in which the MAC was implicated was myasthenia gravis, 
an autoimmune disease characterized by the loss of acetylcholine receptors from 
the motor end plate, resulting in extreme muscle fatigability46. Anti-C9 antibodies 
were used to localize the MAC at the end plate, and a role of the MAC in 
acetylcholine receptor loss was proposed A requirement for terminal complement 
components, specifically C6, has been demonstrated in a model of myasthenia 
gravis, experimental myasthenia induced in rats by inoculation with antibodies to 
the acetylcholine receptor, thus demonstrating that, at least in this model, MAC 
formation is essential for disease expression. It has been suggested that the MAC 
causes 'focal lysis' of the junctional membrane resulting in loss of membrane and 
acetylcholine receptors 
Multiple sclerosis is a common neurological disease characterized by 
widespread demyelination within the central nervous system. The pathogenesis of 
the disease is obscure, though many factors have at various times been implicated. 
The first evidence suggestive of a role of the MAC came from the demonstration 
that the concentration of the terminal complement component C9 was reduced in 
cerebrospinal fluid from patients with this disease47, implying its utilization in 
MAC formation. Non-lethal effects of the MAC demonstrated at the cellular level 
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in vitro may therefore be, at least in part, responsible for the relapsing and remitting 
course of the clinical disease. 
The C5b-9 MAC has also been recently reported to mediate mesangial cell 
apoptosis in experimental glomerulonephritis. Separating the role of the C5b-9 
membrane attack complex from earlier complement components by examining the 
effects of cobra venom factor (which depletes all complement components and 
prevents the generation of the anaphylotoxins C3a and C5a, as well C5b-9, etc.) 
and isolated C6 deficiency by using C6-deficient PVG rats48 (which can generate 
C3a and C5a but are unable to form the C5b-9 membrane attack complexes), it was 
found that complement is the principal inducer of endothelial cell apoptosis in 
antibody-mediated glomerulonephritis. This effect was mediated primarily by 
sublytic C5b-949. 
1.3 Adaptive Immunity 
The adaptive immune system is composed of lymphocytes that are 
important for prevention and elimination of pathogen growth. They consist 
primarily of T cell and B cells. T cells are endowed with T cell receptors and B 
cells possess the ability to generate and secrete antibody. Two of the defining 
features of the adaptive immune system are specificity and immunological 
memory. Specificity in the adaptive immune system is achieved by a combination 
of DNA recombination and somatic hypermutation. Both these processes confer 
diversity of receptors to the cells of the adaptive immune system. Due to this, unlike 
the innate immune cells which can only recognize molecular patterns, the adaptive 
immune system can recognize antigens and respond appropriately. Immunological 
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memory is conferred to cells of the adaptive immune system though the process of 
clonal expansion and maintenance of memory cells. If a T or B cell becomes 
activated by binding to foreign molecules, it starts replicating, generating a huge 
colony of cells that specifically recognizes a particular epitope of an antigen. 
Immunological memory forms the basis for the strategy of  vaccinations which are 
given to children. 
There are two major phases of the adaptive immune response to a pathogen: 
the recognition phase and the effector phase. The recognition phase consists of the 
receptors of a T or B cell binding to the antigen. T cells bind to a peptide derived 
after processing of the antigen and presentation on MHC molecules on antigen 
presenting cells (APCs) such as dendritic cells or macrophages. The T cell receptor 
(TCR) binds to the peptide MHC complex which constitutes the first of two signals 
needed for T cell activation. The second signal, called costimulation, is also 
expressed on APCs after the activation through PRRs. These costimulatory 
molecules are typically CD80 and/or CD86. The first and the second signals 
activate the T cells to clonally expand and differentiate to effector cells or memory 
cells. B cells on the other hand do not need antigen presentation as they bind to the 
antigen directly. Their activation threshold is lowered if the antigen is opsonized 
by complement by engaging CD21 on B cells. Once activated the B cells expand 
clonally and secrete antibodies after differentiating to plasma cells. The effector 
phase consists of modulation of the immune response to tailor to the pathogen and 
promote the release of antimicrobial products. In this phase cells of the adaptive 
immune system cooperate with all the cells of the innate immune system to promote 
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immunity against the specific pathogen. The immune response can be crudely 
classified into two components: cell mediated immune response and humoral 
immune response. Cell mediated immunity is mainly mediated by T lymphocytes. 
This response is generated against intracellular microbes, which survive and 
proliferate inside host cells. Cell mediated immunity can lead to the destruction of 
the microbes or the lysis of the infected cells. Humoral immunity is mediated by 
antibodies, which are produced by B lymphocytes. Antibodies specifically 
neutralize antigens, and target them for elimination by other effector mechanisms, 
such as complement. 
1.4 Leishmaniasis 
Leishmaniasis is a disease that is endemic in regions of the Middle East, 
South America, South Asia, and Africa. According to WHO estimates, 
Leishmaniasis affects 12 million people in 88 countries with two million new cases 
every year50. Leishmania spp is a protozoan parasite that can be transmitted by the 
bite of sand flies (Phlebotomus and Lutzomyia). There are four different forms of 
the disease: visceral, cutaneous, muscocutaneous and diffuse cutaneous. Almost 
90% of visceral leishmaniasis cases in the world are found in India, Brazil and 
Bangladesh. Recently it has been found that patients infected with HIV have 
increased risk to contract leishmaniasis. In turn, infection with Leishmania spp. 
facilitates in establishing the clinical symptoms of AIDS through synergistic 
immuno-suppression. This compounds the problems associated with the treatment 
of patients that suffer from HIV/Leishmania co-infection51. 
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The Leishmania parasite spends half of its life cycle as a motile 
promastigote that lives in the gut of the sandfly and the other as a non-motile 
amastigote that lives inside host macrophages. The procyclic promastigotes can 
divide in the gut of the fly, and then become metacyclic to be able to infect 
mammalian hosts. Once transmitted into the host, these parasites can quickly 
differentiate into amastigotes after being taken up by macrophages. The 
amastigotes can then divide in the phagolysosomes of macrophages and are 
eventually released when these phagocytes burst. These released parasites are taken 
up by neighboring macrophages, thus gaining access into surrounding tissue 
through the mononuclear phagocyte system. When an uninfected sandfly takes a 
blood meal from the infected host, the amastigotes taken up into the fly can 
differentiate into promastigotes in the sand fly and the cycle repeats itself. 
Leishmania infection in mice has long been considered by immunologists 
as a model to study the immune response by a host. BALB/c mice are naturally 
more susceptible to Leishmania major infections due to the development of an 
ineffective Th2 immune response against the parasites Other strains like C57BL/6 
and C3H are able to control the infection due to their ability to raise an effective 
Th1 response predominated by the cytokine IFNγ, which is able to activate 
macrophages to kill the parasite and eliminate the infection52. 
Leishmania spp. activate the alternative complement pathway53. 
Interactions between complement and Leishmania are important for two different 
(and possibly opposite) reasons. First, the opsonization of the parasite by 
complement can target these organisms to macrophages and promote parasite 
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phagocytosis. This can actually be an advantage to the parasite which replicates 
inside macrophages. Second, complement activation can also result in the 
deposition of the terminal components of complement to lyse the parasite. 
Complement is thought to be important in resistance against Leishmania in humans, 
as it has been shown that nearly 90% of all promastigotes can die within 3 minutes 
in medium containing 50% normal human serum (NHS) at 37°C54. Complement 
thus forms an important arm of the innate immune system to exert a strong selective 
pressure on the promastigotes. However, Leishmania employs several mechanisms 
to subvert and evade the complement system. Lipophosphoglycan (LPG) can 
activate the alternative pathway of complement and enables Leishmania to target 
macrophages as the host cell. At the same time LPG can also protect Leishmania 
from complement attack as the LPG coat on its surface becomes longer during 
differentiation into the infective metacyclic stage, thereby providing a physical 
barrier for the insertion of MAC. Another Leishmania surface molecule called gp63 
cleaves the membrane bound C3b molecule into the inactive iC3b form, which then 
acts as a ligand for the macrophage CR3 receptor. Thus LPG and gp63,  can  protect 
the parasite from complement-mediated lysis and  are considered to be important 
virulence factors55. 
1.5 Summary 
The predominant function of the complement system is to “complement” 
the activity of antibodies and provide the first line of defense against pathogens. It 
also shapes the immune response by facilitating recruitment of leukocytes, 
opsonizing pathogens for phagocytosis, and regulating the adaptive immune 
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response by interacting with various receptors. In this study, I elucidate a new 
function of the complement system where it activates leukocytes during 
complement-mediated phagocytosis, resulting in the activation of the NLRP3 
inflammasome though the formation of MAC on their cell surfaces. Leishmania 
major is considered to be a silent pathogen that does not induce any cytokines or 
antimicrobial factors from the host macrophages during infection. Leishmania 
major, by activating complement, is shown here to influence cytokine production 
in macrophages through the activation of NLRP3 inflammasome. The 
inflammasome, a previously uncharacterized player in Leishmania infection, is 





Chapter 2: Materials and Methods 
2.1. Mice 
C57BL/6, Balb/C, C5 deficient (B10.D2-Hc0 H2d H2-T18c/oSnJ), C5 
sufficient (B10.D2-Hc1 H2d H2-T18c/nSnJ) and OT-II transgenic mice, which 
were 6-10 weeks of age were purchased from The Jackson Laboratory (Bar Harbor, 
ME). All mice were maintained in high efficiency particle air-filtered Thoren units 
(Thoren Caging Systems, Hazleton, PA) at the University of Maryland. All animal 
studies were reviewed and approved by the University of Maryland Institutional 
Animal Care and Use Committee. The generation of Nlrp3-/-, Asc-/-, and Casp1-/- 
mice has been described previously 33 
2.2. Reagents 
ATP, zymosan, and inulin were purchased from Sigma-Aldrich (St. Louis, 
MO). Glybenclamide and Compstatin were purchased from Tocris Bioscience 
(Bristol, UK). Normal human serum, serum deficient for complement proteins C3, 
C5, C6, C8 or C9, and purified C5b6, C7, C8, C9 proteins were purchased from 
Complement Tech (Tyler, TX). Particulate inulin was prepared by dissolving one 
gram of inulin in 40 ml water containing 0.1% ammonia and heated at 60°C. Inulin 
was frozen at -20C overnight and subsequently precipitated at 37°C for 3 days in 
the presence of chloroform. The resulting precipitate was centrifuged at 2000xg for 
10 min and re-suspended in water to a concentration of 10mg/ml and stored as 1 ml 




2.3. Murine Macrophages 
Bone marrow derived macrophages (BMMϕ) were prepared as previously 
described56 Briefly, bone marrow cells was flushed from the femurs and tibias of 
mice with PBS+penicillin/streptomycin and cells were plated in petri dishes in 
DMEM/F12 supplemented with 10% FBS, 10 mM L-glutamine, 100 IU/ml 
penicillin, 100 µg/ml streptomycin, and 20% conditioned medium from the 
supernatants of M-CSF secreting L929 (LC14) fibroblasts conditioned medium 
(LCCM).Cells were fed with the same media on day 3. On day 7, macrophages 
were removed from petri dishes and cultured in above mentioned media without 
LCCM.  
RAW264.7 cells were obtained from American Type Culture Collection 
(Manassas, VA) and maintained in DMEM with 10% FBS with penicillin, 
streptomycin and glutamine. 
2.4. Human Macrophages 
Human peripheral blood mononuclear cells (PBMCs) were obtained from 
healthy volunteers with their informed consent in accordance with the Declaration 
of Helsinki and institutional review board approval. The mononuclear cells were 
separated by Ficoll-Hypaque density gradient centrifugation. .Monocytes were 
purified by attachment to culture dishes and differentiated into macrophages in the 
presence of DMEM medium supplemented with 10% heat inactivated human AB 





Leishmania major Friedlin strain, clone V1 (MHOM/ IL/80/Friedlin), Ds-
Red L. major, parasites were maintained as previously described57 Stationary-phase 
promastigotes were propagated in 50:50 Schneider’s insect medium (Sigma-
Aldrich) and M-199 (Invitrogen) supplemented with 10% FBS, 100 U/ml 
penicillin, 100 µg/ml streptomycin, and 2 mM glutamine at 25˚C. Transgenic Ds-
Red L. major parasites were grown in the presence of 50 µg/ml of Geneticin (G418; 
Sigma- Aldrich). 
2.6. Stimulation of bone marrow–derived macrophages 
BMMϕ were primed with 10 ng/ml Ultrapure LPS (Invivogen, San Diego, 
CA), for 4-6 hrs. LPS-primed BMMϕ were either challenged with 1:10 multiplicity 
of infection of Leishmania major, or were treated with ATP/zymosan/inulin at 
concentrations (1mM to 5mMin the presence or absence of 5% of normal human 
serum for 4 hrs. Supernatants were collected and assayed for IL-1β or IL-18. 
Antibody pairs for IL-1 ELISA were purchased from eBioscience (San Diego, 
CA) and for IL-18 ELISA from MBL International (Woburn, MA). 
2.7. Cell Viability and FLICA Staining 
Viability of BMMϕ was assessed by 7AAD and Annexin V staining 
(Molecular Probes). FAM-FLICA™ Caspase-1 assay was performed following 
manufacturer’s protocol (Immunochemistry Technologies, Bloomington, MN). 
Cells positive for active caspase-1 were quantified by flow cytometric analyses. 
2.8. Invitro Leishmania killing assay 
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1x105BMMϕ were plated on glass coverslips in a 24 well plate in 500µl 
DMEM media with 10% FBS and incubated overnight. The cells were stimulated 
with 20ng/ml IL-1β, 100U/ml IFNγ, 10µg/ml LMW-HA in appropriate wells. Ds-
Red Leishmania promastigotes were added to each well at a ratio of 10 Leishmania 
parasites to 1 macrophage with 5% C5 deficient serum (serum from DBA2 mice).  
After 48 hours incubation, the cells were lysed with 1% triton-X solution in water. 
Leishmania viability was quantified by measuring the total amount of DsRed 
fluorescence using a fluorometer. The results were normalized with total protein 
concentration from the cell lysates as determined by absorbance at A280. 
2.9. Lentiviral transduction 
Lentivirus was produced in human embryonic kidney (HEK293T) cells 
transfected with the FUGW-based expression vector encoding CFP-ASC (a kind 
gift from Dr. Katherine Fitzgerald), lentiviral packaging plasmid psPAX2 and 
envelope plasmid pMD2.G using TransIT®-293 Transfection Reagent (Mirus Bio, 
Madison, WI). Supernatants containing lentivirus were collected after 48 hours and 
were used to infect RAW264.7 cells. 
2.10. Immunofluorescence 
For immunofluorescence imaging BMMϕ were cultured on cover slips, 
LPS-primed and activated with AlexaFluor®488-conjugated zymosan A (source S. 
cerevisiae; Life Technologies) or Ds-Red expressing L. major. To visualize 
complement MAC deposition on macrophages, C9-deficient (C9-D) serum was 
supplemented with Alexa647-labeled C9 protein at the time of image acquisition. 
Labelling of C9 protein with Alexa647 was performed following the 
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manufacturer’s protocol (Alexa647 protein labelling kit, Life Technologies, Grand 
Island, NY). Cells were fixed with 4% paraformaldehyde, 3 min after C9 addition 
when the MAC deposition was found to occur at maximum on surface. Cover slips 
were mounted on clean glass slides using Fluoromount-G (Electron Microscopy 
Sciences, Hatfield, PA).  
To visualize inflammasome activation, RAW264.7 cells grown on cover 
slips were transduced with Lentivirus encoding CFP-ASC, LPS-primed and 
activated with Alexa488 conjugated zymosan A in the presence of 5% normal 
human serum for 45 min. The cells were then fixed and imaged under Leica SP5X 
Confocal Microscope (Leica, Exton, PA), in 100X oil immersion objective with 
numerical aperture of 1.32. The fluorochromes were excited using argon laser for 
Alexa-488 and white light laser for Ds-Red and Alexa-647 set at appropriate 
excitation wavelengths.  The images acquired using Leica LAS software and 
processed with LASAF Lite and Adobe Photoshop CS4.  
2.11. In vivo experiments 
For in vivo models of inflammasome activation, the complement-activating 
and complement-depleting functions of cobra venom factor (CVF) were exploited 
in this study. Age-matched male C5 deficient or sufficient mice were injected with 
2U/mouse CVF (Quidel, San deigo, CA) and 20 mg/kg LPS intraperitoneally. After 
3 hours, blood was collected by penetrating the retro-orbital sinus of mice to 
measure serum levels of IL-1β by ELISA. To examine if complement activation 
plays a role in leukocyte infiltration, C57Bl/6 mice were injected with saline or 
1mg of inulin particles intraperitoneally and assessed for intraperitoneal infiltration 
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of GR1 (1A8) positive cells after 6 hrs in peritoneal lavage in mice previously 
complement-depleted with CVF. CVF was administered 24 hrs to prior to inulin 
administration at 2U/mouse concentration. The percentage of GR1 positive cells 
were assessed by flow cytometry. 
2.12. T cell Activation 
Spleen were removed from mice and placed in a petri-dish filled with PBS. 
Single cell suspension was obtained after the spleen or lymph nodes were meshed 
with a plunger of 10-ml syringe through cell strainer of 70μm nylon (BD 
Biosciences, San Jose, CA). CD4+ T Cells Isolation Kit (Miltenyi Biotec Inc) was 
used to magnetically separate and purify T cells from these single cell suspension 
solutions following the manufacture’s recommendation. 
For antigen presentation, macrophages were plated at the concentration of 
2×105/well and primed with 10ng/ml LPS for 4 hrs. Cells were then washed, and 
activated with 150 μg/ml OVA and inflammasome activators like inulin (100 
µg/ml) in the presence of human serum (5%). Alternatively purified complement 
proteins C5b6 (2µg/ml), C7, C8, C9 (10µg/ml each) alone were added to 
macrophages to activate inflammasome. Macrophages were washed after 2 hours 
and co-cultured with 5×105 CD4+T cells for a week. Following primary 
stimulation, CD4+ T cells were harvested, washed, and re-stimulated with 
immobilized CD3 antibodies (BD Biosciences, CA) for 48 hrs. Levels of IL-17 
were measured in the supernatants following secondary stimulation (BD 
Biosciences, CA). 
2.13. Statistical Analysis 
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Data analysis was performed using SigmaPlot (Systat Software, San Jose, 
CA) and analyzed using the Student’s t-test. The statistical differences between 
groups, with the p-values are indicated in the related graphs as: *, p < 0.05; **, p < 




Chapter 3: The Role of Complement induced 
phagocytosis in activating NLRP3 inflammasome 
 3.1. IL-1β production following complement mediated phagocytosis 
The ability of complement opsonized particles to activate macrophages 
were tested by incubating particles with macrophages along with normal serum 
(that serves as a source of complement). Different particles were chosen depending 
on their ability to activate complement. As shown in Figure 3A zymosan and inulin 
particles were potent activators of the alternative complement pathway whereas 
latex beads were not. These particles were added to LPS-primed murine 
macrophages, and the release of IL-1β was measured in supernatants following 
phagocytosis. Zymosan is a potent activator of the alternative complement 
pathway. Increasing doses of zymosan were added to macrophages in the presence 
or absence of normal human serum as a source of complement proteins. Zymosan 
bound avidly to macrophages in the presence or absence of serum (Figure 3B), but 
only serum-opsonized zymosan activated complement and induced robust release 
of IL-1β from macrophages (Figure 3B). As a control for these studies latex beads, 
which do not activate complement were added to macrophages (Figure 3A). These 
beads bound avidly to macrophages in the presence or absence of serum, and 






Figure 3: IL-1β production following complement mediated phagocytosis: 
(A) Complement consumption to measure Alternative Complement Pathway activation by 
zymosan (black circles), inulin (green triangles), and latex beads (red circles) was assessed by 
analyzing the percent of unlyzed rabbit red blood cells. The percent lysis was measured at 550 nm 
to detect released hemoglobin after 30 minutes of incubation. (B) The phagocytosis of zymosan 
by mouse bone marrow derived macrophages (BMMϕ) was measured in the presence (closed 
circles) or absence (open circles) of 5 % normal human serum. The number of particles per 100 
macrophages was counted under a 400X light microscope. Phagocytic index represents the average 
number of particles/macrophage (3 experiments). (C) IL-1β secretion by LPS primed macrophages 
was measured four hours following incubation with increasing amounts of zymosan in the 
presence (closed circles) or absence (open circles) of normal human serum (3 experiments). (D) 
The phagocytosis of latex beads by mouse bone marrow derived macrophages was measured in 
the presence (closed circles) or absence (open circles) of 5 % normal human serum. The average 
number of particles per 100 macrophages was counted and expressed as phagocytic index (2 
experiments). (E) IL-1β secretion by LPS primed macrophages was measured four hours following 
incubation with increasing amounts of latex beads in the presence (closed circles) or absence (open 






 3.2. Effect of opsonization on macrophage activation 
Macrophages are important components in the immune system as they are 
often the first cells to come in contact with foreign pathogens. Serum opsonins 
like complement and antibodies help in detecting these pathogens and targeting 
them for destruction though phagocytosis in macrophages. To evaluate the 
specificity of this effect, we added another control particle, IgG coated sheep red 
blood cells (SRBCs), which bind to macrophage Fcγ receptors. We also added 
another complement activator, called inulin. Inulin is a polysaccharide that has 
been previously shown to be an efficient activator of complement. We were not 
able to detect any cytokine response by macrophages in response to IgG 
opsonization in complement free conditions (Figure 4A) but we could readily 
detect IL-1β secretion from complement opsonized inulin. IL-1β secretion from 
macrophages did not occur when serum complement was inactivated by heat 
(Figure 4B). 
 3.3 Secretion of inflammasome effectors following complement activation 
The release of IL-18 from macrophages was also examined, and there was a 
similar dose-dependent release of IL-18 from macrophages following their 
interaction with zymosan (Figure 5A) in the presence but not the absence of 
complement. Thus complement-mediated phagocytosis by macrophages results in 
the release of IL-1β And IL-18. IL-1β is a protein made as an inactive zymogen, 
pro-IL-1β. The ELISA antibody pair does not discriminate between the 
cleaved/active form and the pro form of IL-1β. To analyze the specific form that 




The IL-1β that was released from macrophages was in the mature/cleaved form, 
because little pro-IL-1β was detected in the supernatants of these cells following 
the phagocytosis of complement-opsonized inulin as shown in Figure 5B. The 
role of complement was implied from the lack of activation seen when particles 
are opsonized with heat inactivated serum. To validate the importance of 
complement, Compstatin, a cyclic tridecapeptide that is a potent C3 inhibitor, was 
added to macrophages in the presence of normal serum with inulin. The induction 
of IL-1β by inulin occurred when inulin was added to macrophages in the 








Figure 4: IL-1β production from particles opsonized with IgG or complement: 
(A) IL-1β release (open triangles, right axis) following IgG-SRBC phagocytosis. The phagocytic 
index (left axis, closed circles) represents the average number of IgG-SRBC/macrophage (B) IL-
1β secretion by LPS primed macrophages was measured four hours following incubation with 
increasing amounts of inulin in the presence (closed circles) of 5% normal human serum or 5% 








Figure 5: Macrophage activation following phagocytosis of opsonized particles: 
(A) IL-18 secretion by LPS primed macrophages was measured four hours following incubation 
with zymosan (10 µg/ml) (closed circles) or vehicle control (open circles) and increasing 
concentrations of normal human serum (2 experiments). (B) Total IL-1β (open triangles) and pro-
IL-1β (closed circles) were measured in supernatants by ELISA four hours after incubating 
macrophages with 100 µg/ml inulin and increasing concentrations of normal human serum. (C) 






 3.4. Membrane Attack Complex induced secretion of IL-1β 
To identify the complement components necessary for macrophage 
inflammasome activation, serum deficient in specific complement components was 
examined. Macrophages failed to secrete IL-1β in response to complement 
activation by inulin when any individual complement proteins were depleted from 
serum (Figure 6A). This included serum deficient in the terminal components, C8 
and C9, indicating a role for the membrane attack complex (MAC) in IL-1 release. 
To directly show that the MAC complex was required for inflammasome activation, 
the terminal complement components C5b, C6, C7 C8 and C9 were directly added 
sequentially to LPS-primed macrophages to assemble the MAC on the macrophage 
plasma membrane. IL-1β was only detected in cells exposed to the complete C5b-
9 membrane attack complex (Figure 6B).  
3.5. NLRP3 inflammasome activation during complement-mediated 
phagocytosis.   
Macrophages have a number of pattern recognition receptors (PRRs) that 
can sense danger and promote host inflammatory responses. One of the receptors, 
NLRP3, is present in the cytosol and is believed to sense cytosolic danger through 
ionic imbalance and increased reactive oxygen species generation. We 
hypothesized that complement-mediated phagocytosis could cause the activation of 











Figure 6: Macrophage activation by complement membrane attack complex: 
(A) IL-1β secretion was measured in supernatants following the incubation of macrophages with 
inulin (100µg/ml) plus normal serum or serum deficient in individual complement components. 
(B) IL-1β secretion was measured in supernatants of macrophages after the addition of purified 




To investigate the role of inflammasome activation following phagocytosis, 
BMMϕ from mice deficient in NLRP3, NLRC4, ASC, or caspase-1 were examined 
and compared to macrophages from WT mice. LPS-primed macrophages from WT 
or NLRC4-/- mice secreted IL-1β in response to complement activation by inulin 
(Figure 7A), zymosan (Figure 7B) or L. major (Figure 7C). However, macrophages 
from mice deficient in NLRP3, ASC, or caspase-1 failed to secrete detectable IL-
1β. Caspase-1 activation was directly measured by FLICA staining of 
macrophages. Macrophages responding to complement activation by zymosan 
inulin or L. major exhibited caspase-1 cleavage. Incubation of these particles in 
serum deficient in the sixth component of complement failed to induce caspase-1 
activation (Figure 8).  
To visualize inflammasome formation, a macrophage-like cell line 
RAW264.7, which does not express endogenous ASC, was transduced with CFP-
ASC and exposed to complement activators.  These macrophages were primed 
with LPS for four hours and then exposed to fluorescent Zymosan particles in the 
presence of normal serum. ASC-specks were observed in macrophages that 
actively took up zymosan (Figure 9A, B). The ASC specks were not observed in 
the cells that received zymosan without normal serum (Figure 9C). The specks 
observed were very similar in size but not as plentiful as those in macrophages 






Figure 7: NLRP3 inflammasome activation during complement-mediated phagocytosis.  : 
IL-1β production from LPS primed bone marrow derived macrophages (BMMϕs) from wild type 
(WT) mice (closed circles) or mice deficient in NLRP3 (open circles), ASC (grey squares), 
caspase-1 (closed inverted triangle), or NLRC4 (open triangle) was measured by ELISA following 













Figure 8: NLRP3 inflammasome activation during complement-mediated phagocytosis: 
(A) Caspase-1 positive cells were assessed by flow cytometry using a FAM-FLICA dye based 
assay. Cells were primed with LPS for 6 hours followed by antigen stimulation in the presence 
of 5% complete or C6D human serum. Representative FACS plots of FLICA staining following 
activation of LPS primed macrophages by (B) zymosan or (C) inulin with normal serum (blue) 













Figure 9: Visualization of Inflammasome activation following complement activators.   
ASC-CFP transduced macrophages (red) were LPS primed for four hours. There were then 
activated by Alexa488 conjugated zymosan (green) and serum (A and B) or zymosan alone for 
45mins (C) or by ATP (D) for 20mins.  Cells were visualized using Leica SP5 X Confocal 
Microscope. 
D C A B 
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3.6 Chapter summary: 
The activation of complement pathway is known to induce and acute inflammatory 
response. These responses not only induce recruitment of cells to the site of infection but 
also induces the activation of cells to produce cytokines required to promote an immune 
response. The induction of inflammation by complement was previously thought to be 
solely due to the production of anaphylatoxins C3a and C5a. In this study, we show that 
the MAC can induce the activation of macrophages by activating the assembly of the 
NLRP3 inflammasome. This activation has been shown to induce the maturation and 
release of IL-1β and IL-18, both of which have been implicated in the promotion of acute 
phase responses and inflammation58. The MAC proteins can be now seen as attractive 
targets to modulate inflammatory conditions as it has been shown to directly induce the 
activation of macrophages and promote cytokine secretion. The activation though MAC 
regardless of the type of particle being used also raises the possibility that NLRP3 
inflammasome plays an important role in the acute responses against any pathogen that 






Chapter 4: Activation of Membrane Attack Complex and its 
role in promoting inflammation through NLRP3 
 4.1 Membrane Attack Complex Bystander Effect 
Complement activation contributes to host defense though opsonization of 
particles and lysis of target cells though the membrane attack complex (MAC). 
Complement activation also leads to inflammation, and people with genetic 
deficiencies in complement regulatory proteins frequently suffer from 
inflammatory immunopathology. Although complement–mediated inflammation 
has been largely attributed to the generation of the complement anaphylotoxins, 
C5a and C3a, it is currently unclear if the MAC also plays a role in promoting an 
acute inflammatory response. We showed the importance of MAC in 
inflammasome activation, but it became important to determine how the MAC 
interacted with the plasma membrane of the macrophage. 
The “reactive lysis” of unsensitized erythrocytes by the complement MAC 
was first described by Lachmann and colleagues in 1970. These early studies 
demonstrated that the terminal complement components were not irreversibly 
bound to target particles, but rather could “jump” to neighboring un-sensitized 
“bystander” erythrocytes. This could result in the lysis of RBCs that were 
themselves not activators of complement. Although the bystander mechanism 
47 
 
proved to be helpful for the study of the structure and function of the MAC in later 
years, the physiological relevance of this phenomenon remained unclear. In light 
of our previous observations, this provided a mechanistic hypothesis as to how the 
MAC could form on the macrophages leading to NLRP3 activation and result in 
inflammation (Figure 10). 
To demonstrate bystander activation in this work, the original description 
of “reactive lysis”, was adapted to detect macrophage inflammasome activation. 
Complement pathway can be crudely divided into two phases: the activation step 
and the execution step. The activation step (regardless of way complement pathway 
is initiated through the classical, lectin or the alternative pathway), is primarily a 
series of proteolytic steps that requires divalent ions like Mg2+ and Ca2+ as 
cofactors. The products of this pathway form functional convertases that interact 
with the surface of the target particle by forming a covalent bond. The execution 
step which, involves the assembly of MAC involves protein interactions between 
C5b, C6, C7, C8 and C9 and inserts into the target particle through hydrophobic 
interactions (Figure 11). In the reactive lysis experiments, the complement C5 
convertase was formed on the surface of a complement-activating particle, such as 
inulin, by incubating inulin with complete serum in 5mM Mg2+/EGTA at 17°C. 
This enables effective formation of convertases on the surface of inulin by allowing 
the activation step to proceed. The inulin was then washed and added to 
unsensitized RBCs in the presence of serum and 3mM EDTA, conditions which 
block complement activation but allow the non-enzymatic formation of the MAC 

















Figure 10: Bystander activation induced inflammasome activation.   
The process of phagocytosis brings into close contact any complement activating pathogen and 
macrophages. The assembly of the membrane attack complex (MAC) takes place on the 
complement convertases present on pathogens. The MAC is then either formed on pathogens to 
effect lysis or on host macrophages to induce inflammasome activation through the K+ efflux 









Figure 12: Salient features of complement activation.   
The complement pathway can be divided into two main parts: the activation step and the 
execution step. Although complement can be activated through any of the three activation 
mechanisms, they share common features like requirement of divalent ions as cofactors, and 
being bound covalently to target particles. The execution step primarily involves the assembly of 
the membrane attack complex that involves assembly of multiple proteins (C5b, C6, C7, C8 and 
C9. This step does not require divalent ions and products of this step interact with the particle 
though hydrophobic interactions to establish a MAC pore. 
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The lysis of “bystander” RBCs under these conditions indicates that the 
MAC had been transferred onto RBCs after being activated by the C3-convertase 
previously formed on inulin (Figure 12A)39.A similar approach to the reactive lysis 
system was taken, but adding macrophages as the bystander acceptor cell. Rather 
than measuring lysis, IL-1β secretion from macrophages was measured. A serum 
dose-dependent increase in IL-1β secretion by macrophages was observed under 
these conditions indicating that complement activation can induce IL-1β release 
from “bystander” macrophages (Figure 12B). 
To demonstrate that this phenomenon occurs across mammalian species, 
homologous human and mouse systems were compared. Human macrophages 
release IL-1β in a human serum dose-dependent manner (Figure 13A), and murine 
macrophages release IL-1β in a murine serum dose-dependent manner in response 
to activation by inulin (Figure 13B). Mouse serum has previously been shown to 
be particularly labile, exhibiting reduced serum lytic activity in vitro, therefore it is 
not surprising that higher concentrations of mouse serum were required to elicit 









Figure 12: Bystander activation following complement mediated phagocytosis.   
(A) The “reactive lysis” of bystander erythrocytes (see Methods) was measured by quantitating 
hemoglobin release from lysed SRBC after incubating C5b-inulin in increasing serum 
concentrations in 3mM EDTA. (B) Inflammasome activation by “bystander” complement 
activation was assessed by measuring the release of IL-1β following co-incubation of 











  Figure 13: Complement mediated phagocytosis induced inflammasome activation across 
species.   
IL-1β secretion from human (A) or mouse (B) macrophages after incubation of inulin plus 




 4.2 Deposition of MAC during phagocytosis 
To visualize MAC formation on the macrophage plasma membrane during 
the uptake of complement-activating particles, fluorescence microscopy was used 
to detect AF-649-tagged C9 deposition.  As expected, C9 was easily visualized on 
the surface of complement-opsonized particles, but MAC formation was also 
detected on the surface of bystander macrophages when Ds-Red expressing L. 
major or zymosan was added to macrophages (Figure 14A). The bystander MAC 
deposition occurred primarily on the surfaces of macrophages actively involved in 
the phagocytosis of complement-opsonized particles, and it also could be visualized 
on the surface of cells directly adjacent to these cells, but not on cells distant from 
those undergoing phagocytosis (Figure 14B). Not all of the macrophages 
undergoing complement-mediated phagocytosis were decorated with C9 (Figure 
14C). As controls, macrophages not receiving complement activators had little to 
no C9 deposition on their surface. C9 could also be detected inside macrophages, 
but we could not determine whether this was due to the endocytosis of MAC by 
macrophages or a bystander transfer occurring within macrophage 









Figure 14: Bystander MAC deposition on macrophages. 
LPS primed BMMϕs were incubated with Ds-Red Leishmania (shown in red, A, B) or zymosan 
AF488 (C) for 3mins with C9 deficient human serum supplemented with AF-647 labelled C9 
(blue). Complement activation was stopped by placing the cells on ice and macrophages were 
stained with (A, B) FITC-F4/80 (green), or (C) PE-F4/80 (green). (A) C9 (blue) was found to be 
deposited on L. major (red) and on the surface of macrophages (green). (B) C9 (blue) was 
deposited on the surface of L. major (red) infected macrophages as well as macrophages 
immediately adjacent to the infected macrophage. (C) C9 (blue) was found on the surface of 







 4.3 Imbalance in Intracellular ions leads to the activation of Inflammasome 
The MAC has been implicated in a variety non-lytic effects that differ 
according to the nature of the target cell. On phagocytes (neutrophils and 
macrophages), the MAC induces K+, ATP, and Ca2+ transport across membranes. 
Each of these molecules has been shown to influence the activation of the NLRP3 
inflammasome. To determine the importance of secreted ATP in complement 
mediated secretion of IL-1β, we used macrophages from P2X7R-/- mice that lacked 
the ability to activate the inflammasome in response to high concentration of 
extracellular ATP. P2X7R-/- macrophages retained their ability to secrete IL-1β in 
response to complement activation by inulin, indicating that MAC-mediated pore 
formation does not require the P2X7R for NLRP3 inflammasome activation (Figure 
15). 
The presence of the MAC pore on the cell surface of host cells can also 
induce reactive oxygen species (ROS) due to mitochondrial stress. As ROS have 
been implicated in NLRP3 activation, we looked into the effect of ROS inhibition 
on IL-1β secretion. The ROS chelator N-acetyl cysteine (NAC) induced a dose 
dependent reduction in IL-1β secretion by LPS-primed macrophages in response to 
inulin and complement (Figure 16A). Pore formation usually induces K+ efflux 
from cells, and this efflux is required for the activation of the inflammasome.  To 
examine the role of K+ efflux in MAC pore induced bystander inflammasome 
activation, K+ efflux was blocked by adding the drug glybenclamide, or inhibited 
by increasing the extracellular concentrations of K+. Both conditions resulted in 
decreased IL-1β secretion in response to the phagocytosis of complement 
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opsonized inulin, indicating that K+ efflux is required for MAC-mediated 






Figure 15: Complement mediated Inflammasome activation is P2X7 independent. 
IL-1β production from macrophages deficient in P2X7 (open circles) was compared to WT 
macrophages (closed circles) after stimulation with increasing concentrations of ATP (A) or 










Figure 16: MAC mediated K+ efflux and ROS production drives inflammasome activation. 
IL-1β production from macrophages was measured by ELISA after inhibiting reactive oxygen 
species by adding increasing concentrations of N-acetyl cysteine (NAC) (A) , or after inhibiting 
potassium efflux by incubating macrophages in increasing concentrations of Glybenclamide (B) 








 4.4 MAC mediated Cell repair and Cell death 
The MAC pore also allows the influx of Ca2+ and increased intracellular 
Ca2+ mediates many of the consequences of MAC insertion. One major 
consequence of Ca2+ influx is the promotion of membrane repair mechanisms in 
macrophages. In the absence of calcium signaling pores on host cells persist to 
induce greater cellular damage leading to apoptosis. Persistent pore accumulation 
on the macrophage plasma membrane could lead to increased inflammasome 
activation due to the persistence of danger signals. To analyze the importance of 
extracellular Ca2+ influx in inflammasome activation we incubated macrophages 
with MAC proteins C5b, C6, C7, C8, and C9 for 4 mins in the presence or absence 
of Ca2+ in the media. To check for the persistence of MAC pore on the plasma 
membrane, propidium iodide (PI) was added for 1 min and the cells were analyzed 
for PI incorporation by flow cytometry. PI is a vital dye and thus is excluded from 
intact viable cells, however if the membrane is compromised due to pores then PI 
can enter the cells and bind to nucleic acids making it fluorescent. We found that 
macrophages incubated with MAC in the absence of Ca2+ had persistent pores even 
after 4 mins, unlike macrophages incubated in normal media (Figure 17A). This 
persistence of MAC on the plasma membrane leads to increased IL-1β when it is 
deposited through bystander activation during phagocytosis of inulin (Figure 17B). 
Thus, membrane repair mechanisms not only prevents excessive inflammasome 


















Figure 17: Ca2+ Mediated Membrane repair and modulation of Inflammasome activation. 
(A) BMMϕ was incubated with Mac proteins in the Ca2+ low or Ca2+ high media for 4 mins. 
The integrity of the membrane after MAC deposition was analyzed by looking into PI 
incorporation through flow cytometry. (B) IL-1β was measured in supernatants of macrophages 





Complement was first recognized because of its capacity, in conjunction 
with antibody to lyse cells. Erythrocytes were among the first cells to be 
investigated with regard to the lytic mechanism of complement action. It has been 
shown that a single functional MAC in the membrane of a metabolically inert, aged 
erythrocyte is sufficient to lyse the cell by colloid osmosis. Unlike erythrocytes that 
can be lysed by a single C5b-9 channel, several channels are required to lyse a 
metabolically active nucleated cell, which appear to require C5b-9 containing 
multimeric C9. The multichannel requirement for nucleated cell lysis has been 
attributed to a defense response of the cell though ion pumps to stabilize membrane 
polarization and to promote elimination of TCC from the PM by endocytosis or by 
endocytosis and vesiculation. Nucleated cells are thus more difficult to kill with 
antibody and complement than are aged erythrocytes or liposomes. To directly 
monitor macrophage viability following bystander complement activation, 
macrophages were stained with 7AAD and Annexin V to measure cell viability. As 
shown in Figure 18, there was little evidence for cell death via apoptosis in response 
to complement activation by inulin or zymosan. Thus, macrophages undergoing 
complement-mediated phagocytosis remain viable while they cleave caspase-1 to 









Figure 18: Macrophage cell death following inflammasome activation with MAC. 
Macrophage viability was measured by the uptake of 7AAD and Annexin V staining after 
incubating LPS-primed macrophages with various complement activators. 
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 4.5 Role of MAC bystander activation in modulating adaptive immunity 
Inflammasome activation in many studies previously has been linked to a 
skewed Th17 adaptive immune response. Macrophages can act as antigen 
presenting cells to promote T cell activation and adaptive immunity.  In addition to 
its role in promoting inflammation in patients with autoimmune diseases, Th17 and 
IL-17 play important roles in the clearance of extracellular bacterial and fungal 
infections. This enables the transition from inflammatory response to an immune 
response against a particular pathogen. To investigate a role for complement 
activation in the modulation of T cell responses, we examined the ability of 
bystander-activated macrophages to serve as antigen presenting cells. LPS primed 
macrophages were pulsed with Ova under conditions where the inflammasome was 
activated, either by the addition of purified MAC components (Figure 19A) or by 
bystander inulin activation (Figure 19B). Ova-specific CD4+ DO.11.10 T cells 
were added to macrophages and incubated for 7 days.  T cells were re-stimulated 
at day 7 using immobilized antibody to CD3. Cytokine production from T cells was 
measured three days later. Bystander complement activation on macrophages 
induced T cells to make significantly higher levels of IL-17A. To verify the 
importance of inflammasome activation in T cell polarization, LPS-primed WT or 
NLRP3-/- macrophages on a BALB/c background were cultured with inulin and 
human serum along with 150µg/ml OVA and added to CD4+OT-II T cells. In 
primary stimulations, CD4+OT-II T cells co-cultured with WT macrophages 
showed an increase in IL-17A production that was not observed when NLRP3-/- 
BMMϕ, were added (Figure 20A). The re-stimulation of T cells showed a similar 
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NLRP3-dependent increase in IL-17A (Figure 20B) production. These data indicate 
that IL-1β, produced as a result of bystander complement activation on 














Figure 19: Bystander complement activation induced modulation of Th cell activation. 
IL-17A production from OVA-specific D011.10 T cells was measured in vitro after stimulation 
with LPS primed Ova-pulsed macrophages in which the inflammasome was activated by purified 















Figure 20: Role of NLRP3 in complement induced modulation of adaptive immunity. 
IL-17A production by OT-II T cells was measured following co-culture with WT (black bars) or  
NLRP3-/- macrophages that were pulsed with OVA under conditions that induced 
inflammasome activation (inulin + serum) or in which the inflammasome was not activated 
(inulin + HI-serum).  (A) Supernatants of primary co cultures of CD4T cell and macrophages (B) 





 4.6 IL-1β induced activation of macrophages and the killing of Leishmania 
Leishmania have developed intricate pathways to disrupt host signaling 
pathways that enable them to survive in macrophages. Thus it has been proposed 
that Leishmania is silent in its entry into macrophages. Leishmania do not induce 
the production of IL-12 from infected macrophages, nor do they induce TNF or 
NO production (data not shown). This is consistent with a quiescent mechanism 
of entry. To ascertain the importance of inflammasome activation in limiting 
Leishmania major replication in macrophages, we activated macrophages using 
culture supernatants of inflammasome activated macrophages. In line with our 
previous observations, Leishmania was not able to provide signals that synergized 
with IFN-γ to enable macrophage activation as measured by nitric oxide 
production. However, inflammasome activated supernatants together with IFN-γ 
activated macrophages to produce significantly higher amount of reactive 
nitrogen species that decreased parasite replication in macrophages in vitro 
(Figure 21A). The results were strikingly similar to TLR agonist and another 
endogenous danger signal, LMW- hyaluronic acid. There also was evidence of 
classical activation of the macrophage as both inflammasome activated 
supernatants and LMW-HA were able to synergize with IFNγ and induce the 
production of reactive nitrogen species NO as shown in Figure 21B. This 
indicates that products of inflammasome activation are capable of contributing to 
the killing of the parasites, like TLR agonists. Leishmania themselves do not 
induce any effector molecules as can be seen by the lack of killing of these 
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parasites in the presence of IFN-γ alone.  Thus, inflammasome activation 















Figure 21: Products of Inflammasome activation synergizes with IFNγ to effect the killing 
of Leishmania major. 
LPS-primed macrophages from WT were pulsed with ATP for 10 mins, and then washed and 
replaced with fresh medium for further incubation. Medium was collected after 1 hrs later. 
Secondary cultures were treated with collected medium (labeled IL-1β), and then infected with 
L. major-RFP for 48 hrs. Cells were lysed using TritonX-100 and lysates were quantified for 




Chapter 5: Conclusions 
Complement has long been recognized to be an integral component of host 
defense. The multiple complement activation pathways share the common 
terminal complement components C5b-C9n, which form membrane attack 
complexes (MAC) that create pores on membranes to cause the osmotic lysis of 
target particles. In this study, we demonstrate that the deposition of sublethal 
membrane attack complexes on macrophages during the process of complement-
mediated phagocytosis can activate host inflammasomes, and thereby affect 
innate and adaptive immunity. It is shown here that IL-1β and IL-18 release from 
macrophages depends on a previously described60 but poorly understood 
“bystander” deposition of MAC on the plasma membrane of phagocytic 
macrophages. The secretion of IL-1β and IL-18 did not occur with macrophages 
deficient in NLRP3, ASC or Caspase-1, indicating that the NLRP3 inflammasome 
is activated during complement-mediated phagocytosis. In this way, complement 
activation during phagocytosis of particles, generates key inflammatory signals 
through inflammasome activation and subsequent IL-1β and IL-18 cytokine 
release.  
The so-called “reactive lysis” of unsensitized erythrocytes by the 
complement MAC was first described by Lachmann and colleagues in 197039. 
These early studies demonstrated that the terminal complement components were 
not irreversibly bound to target particles, but rather could “jump” to neighboring 
un-sensitized “bystander” erythrocytes. This could result in the lysis of RBCs that 
were themselves not activators of complement. Although this bystander 
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mechanism proved to be helpful for the study of the structure and function of the 
MAC, the physiological relevance of this phenomenon remained unclear. The 
present study suggests that this bystander deposition of MAC can occur on 
macrophages during the process of complement-mediated phagocytosis. Instead 
of resulting in reactive lysis it resulted in inflammasome activation and the 
secretion of IL-1β and IL-18 by phagocytic macrophages. Thus, this work 
establishes a new physiological relevance for bystander MAC deposition. 
Bacterial pore forming toxins have been previously associated with the 
activation of host cell inflammasomes61. The poly-C9 MAC also forms pores on 
membranes to cause host cell lysis. However, most eukaryotic cells have efficient 
membrane repair mechanisms to prevent host cell lysis. In particular, the 
expression of CD59 on mammalian cells can inhibit increased C9 deposition to 
prevent cell lysis. Despite these regulatory mechanisms, recent studies have 
shown that directing complement deposition on to host cells , with antibodies to 
cell surface proteins, can result in the activation of host inflammasomes45. This 
suggests that in autoimmune diseases, self-reactive antibodies could contribute to 
inflammation by activating host inflammasomes. In the present work, we 
demonstrate that auto-antibodies are not an absolute requirement to induce 
inflammasome activation in host cells. Rather, the phagocytosis of complement-
opsonized particles alone is sufficient to activate inflammasomes and initiate 
similar inflammatory cascades.  These observations may help explain why 
complement-mediated phagocytosis is associated with more inflammatory 
responses than non-opsonic phagocytosis. 
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The complement MAC has been shown to be involved in exacerbating the 
clinical pathology in a variety of autoimmune and autoinflammatory diseases 
ranging from gout62, to rheumatoid arthritis63 and coronary artery disease64. In 
many cases, antibodies to terminal complement components have been used to 
mitigate inflammation. Eculizimab, a humanized antibody targeting complement 
component C5, is being prescribed for patients with Paroxysmal Nocturnal 
Hemoglobinuria (PNH)65, atypical hemolytic uremic syndrome (aHUS)66, 
glomerulonephritis67, SLE68, and even asthma69. Interestingly, the administration 
of anti-complement antibodies not only prevents host cell lysis, but also reduces 
inflammatory markers in these patients70. It is tempting to speculate that part of 
this may be due to the inhibition of inflammasome induction by bystander 
deposition of MAC on host cells.  
Several groups have proposed that complement can be a natural adjuvant 
to promote immune responses, and that complement activation by adjuvants71 can 
enhance vaccine efficacy72–74. Complement activation is thought to play an 
important role in the adjuvant effects of alum75, and novel adjuvants based on 
inulin have been shown to be potent inducers of Th1 and Th2 immune response
76. 
Complement-opsonized antigens, like HIV72,74 and anthrax77, are better at 
activating T cells than their unopsonized counterparts. In the present studies we 
demonstrate that complement activation can be causally linked to IL-1β and IL-18 
secretion by macrophages. This can have myriad effects on innate and adaptive 
immune responses. IL-1β is a potent proinflammatory cytokine that is known to 
induce fever, upregulate acute phase proteins, and induce adhesion molecule 
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expression on endothelial cells27. IL-1β is important for the development of Th17 
responses which can confer immunity to fungi, such as C. albicans78. IL-1β 
production has been associated with increased resistance to M. tuberculosis79, and 
in some scenarios IL-1R1 signaling can also promote Th2 responses in mouse 
models of asthma80. IL-18 is a potent inducer of IFNγ from NK cells and T cells, 
and in the presence of IL-12 or IL-15 can potentiate cell mediated immunity. IL-
18 can also combine with IL-23 to promote Th17 responses
81, and with IL-4 to 
promote Th2 responses
82. Therefore the mechanism of complement-mediated 
inflammasome activation provides a novel therapeutic target pathway that is 
relevant in multiple contexts from enhancement of vaccine responses to 
suppression of undesirable immunogenicity and inflammation. Our study also 
suggests that complement induced activation of the inflammasome in 
macrophages may lead to protective immune response against a variety of 
pathogens not only due to the direct lytic or opsonic effects of complement, but 
also by fundamentally changing the immune response to that organism. 
Leishmania spp. is efficient at evading the immune response. In fact, it 
may actively inhibit macrophage responses to IFNγ 83. Previous studies report that 
MyD88 is absolutely essential in promoting protective immunity to Leishmania. 
Since Leishmania does not elicit a proinflammatory response from macrophages, 
it becomes important to study IL-1β and IL-18 signaling because both of these 
cytokines signal through MyD8858. The study of the role of endogenous danger 
signals in regulating immune response during Leishmania spp. infections 
therefore becomes important. The NLRP3 inflammasome complex has been 
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shown to be activated by a number of different danger signals. One of the most 
important substrate for inflammasomes is IL-1β. IL-1β is released early during an 
infection and is capable of modulating many different aspects of innate immune 
response to an infection. Like TLRs, it also signals through a receptor that utilizes 
the adaptor MyD8884. These studies may uncover an unexpected way in which 
complement activation may skew adaptive immune responses. Inflammasomes 
regulate both the maturation of cytokines and also various other cellular activities 
like regulation of apoptosis of an infected cell by sensing danger signals like ATP 
and pore forming proteins. The ability of Inflammasome derived IL-1β to 
synergize with macrophages to initiate killing of parasites, can help us understand 
the mechanism of early control by innate immune system during Leishmania 
infection. It remains to be determined if the modulation of the adaptive immune 
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